A Multicenter Machine Learning-Based Predictive Model of Acute Toxicity in Prostate Cancer Patients Undergoing Salvage Radiotherapy (ICAROS Study).
Source check: Source checked. Not independent scientific confirmation.
Finding: Among 454 patients across three Italian radiotherapy centers, LASSO selected predictors and five ML classifiers/decision trees predicted grade ≥2 acute GI/GU toxicity; 70/30 split validation AUC up to .706 GI and .855 GU. Retrospective, heterogeneous treatments, modest internal validation. The reviewed source supports this bounded result; external generalization, causal effects, and sustained operational impact remain unestablished where the source reports retrospective or internal evaluation.
Technology: Among 454 patients across three Italian radiotherapy centers, LASSO selected predictors and five ML classifiers/decision trees predicted grade ≥2 acute GI/GU toxicity; 70/30 split validation AUC up to .706 GI and .855 GU. Retrospective, heterogeneous treatments, modest internal validation.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Among 454 patients across three Italian radiotherapy centers, LASSO selected predictors and five ML classifiers/decision trees predicted grade ≥2 acute GI/GU toxicity; 70/30 split validation AUC up to .706 GI and .855 GU. Retrospective, heterogeneous treatments, modest internal validation.
- Test and result
- Among 454 patients across three Italian radiotherapy centers, LASSO selected predictors and five ML classifiers/decision trees predicted grade ≥2 acute GI/GU toxicity; 70/30 split validation AUC up to .706 GI and .855 GU. Retrospective, heterogeneous treatments, modest internal validation.
- Limitation / still unknown
- Among 454 patients across three Italian radiotherapy centers, LASSO selected predictors and five ML classifiers/decision trees predicted grade ≥2 acute GI/GU toxicity; 70/30 split validation AUC up to .706 GI and .855 GU. Retrospective, heterogeneous treatments, modest internal validation.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.mdpi.com/2072-6694/17/13/2142
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.